Study of selected drugs in clinical trials in the pharmacological therapy of COVID-19

Detalhes bibliográficos
Autor(a) principal: Furuzawa, Tatiana Aparecida
Data de Publicação: 2022
Outros Autores: Cardia, Gabriel Fernando Esteves, Iwaki, Mariana Vessoni, Cremer, Edivaldo, Spironello, Ricardo Alexandre, Comar, Francielli Maria de Souza Silva, Cuman, Roberto Kenji Nakamura
Tipo de documento: Artigo
Idioma: por
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/24445
Resumo: COVID-19 is an acute respiratory infection caused by the potentially severe, highly transmissible, globally distributed SARS-CoV-2 coronavirus. The search for drugs that have activity on SARS-CoV-2 is a constant challenge without precedent in the validation of effective drugs in the treatment of patients affected by COVID-19. Objective: This integrative review aimed to assess studies in the scientific literature, involving clinical trials that evaluate the efficacy of drugs already available on the market for probable use in the treatment of COVID-19. Methodology: The search was conducted from April 2020 to June 2021 in the PubMed, SciElo and Lilacs databases, using the Health Science Descriptors (DeCS) "COVID-19", "SARS-CoV-2", "Drugs", "Trials Clinicals", "Treatments". The criteria for inclusion of articles in the search were those with abstract and text available in full electronically, written in English, Portuguese, and Spanish, published from April 2020 to June 2021, in scientific journals, and that evaluated the efficacy of probable drugs in the treatment of COVID-19 and clinical trials in hospitalized patients with the disease. Articles that did not jointly address the topic of the study, duplicate articles in the databases, review articles, articles based on in vitro / in vivo animal trials, articles based on traditional medicine, editorial type studies and also the reflexive articles were excluded. Results: Of the 210 articles identified, 132 were excluded for not meeting the inclusion criteria, and 78 articles that aimed to study drug efficacy in international clinical trials were selected for this study. Of these, 67 were in PubMed, 6 in SciELO, and 5 in Lilacs. A total of 49 drugs were analyzed, classified into 22 pharmacological classes. The main classes of drugs in studies were: direct acting antivirals in monotherapy, 8 (16.32%); immunomodulators, 7 (14.28%); immunomodulators + associations, 2 (4.08%); and immunostimulants + associations, 2 (4.08%). Conclusion: The drugs and their associations under study did not show specific therapeutic efficacy for the treatment of COVID-19; however, clinical trials indicated improvement in patients' clinical symptoms and hospital length of stay. However, some drugs showed significant adverse reactions, directly interfering with patient safety.
id UNIFEI_e7dfd275afdb00efa27c6913b6c9e4d0
oai_identifier_str oai:ojs.pkp.sfu.ca:article/24445
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Study of selected drugs in clinical trials in the pharmacological therapy of COVID-19Estudio de fármacos seleccionados en ensayos clínicos en la terapia farmacológica de la COVID-19Estudo dos fármacos selecionados em ensaios clínicos na terapia farmacológica da COVID-19 COVID-19SARS-CoV-2MedicamentosEnsayos ClínicosTerapéutica.COVID-19SARS-CoV-2MedicamentosEnsaio ClínicoTerapêutica.COVID-19SARS-CoV-2DrugsTrials ClinicalsTherapeutics.COVID-19 is an acute respiratory infection caused by the potentially severe, highly transmissible, globally distributed SARS-CoV-2 coronavirus. The search for drugs that have activity on SARS-CoV-2 is a constant challenge without precedent in the validation of effective drugs in the treatment of patients affected by COVID-19. Objective: This integrative review aimed to assess studies in the scientific literature, involving clinical trials that evaluate the efficacy of drugs already available on the market for probable use in the treatment of COVID-19. Methodology: The search was conducted from April 2020 to June 2021 in the PubMed, SciElo and Lilacs databases, using the Health Science Descriptors (DeCS) "COVID-19", "SARS-CoV-2", "Drugs", "Trials Clinicals", "Treatments". The criteria for inclusion of articles in the search were those with abstract and text available in full electronically, written in English, Portuguese, and Spanish, published from April 2020 to June 2021, in scientific journals, and that evaluated the efficacy of probable drugs in the treatment of COVID-19 and clinical trials in hospitalized patients with the disease. Articles that did not jointly address the topic of the study, duplicate articles in the databases, review articles, articles based on in vitro / in vivo animal trials, articles based on traditional medicine, editorial type studies and also the reflexive articles were excluded. Results: Of the 210 articles identified, 132 were excluded for not meeting the inclusion criteria, and 78 articles that aimed to study drug efficacy in international clinical trials were selected for this study. Of these, 67 were in PubMed, 6 in SciELO, and 5 in Lilacs. A total of 49 drugs were analyzed, classified into 22 pharmacological classes. The main classes of drugs in studies were: direct acting antivirals in monotherapy, 8 (16.32%); immunomodulators, 7 (14.28%); immunomodulators + associations, 2 (4.08%); and immunostimulants + associations, 2 (4.08%). Conclusion: The drugs and their associations under study did not show specific therapeutic efficacy for the treatment of COVID-19; however, clinical trials indicated improvement in patients' clinical symptoms and hospital length of stay. However, some drugs showed significant adverse reactions, directly interfering with patient safety.La COVID-19 es una infección respiratoria aguda causada por el coronavirus SARS-CoV-2, potencialmente grave, altamente transmisible y de distribución mundial. La búsqueda de fármacos con actividad contra el SARS-CoV-2 es un reto sin precedentes y constante en la validación de fármacos eficaces para el tratamiento de pacientes con COVID-19. Objetivo: Esta revisión integradora tuvo como objetivo evaluar los estudios en la literatura científica, con ensayos clínicos que evalúan la eficacia de los medicamentos ya disponibles en el mercado para su probable uso en el tratamiento de la COVID-19. Metodología: La investigación se llevó a cabo en el período de abril de 2020 a junio de 2021 en las bases de datos PubMed, SciElo y Lilacs, utilizando los buscadores de ciencias de la salud (DeCS) "COVID-19", "SARS-CoV-2", "Medicamentos", "Ensayo Clínico", "Terapéutica". Los criterios de inclusión de los artículos en la búsqueda fueron aquellos con resumen y texto disponible en formato electrónico completo, escritos en inglés, portugués y español, publicados entre abril de 2020 y junio de 2021, en revistas científicas y que evaluaran la eficacia de probables fármacos en el tratamiento de la COVID-19 y ensayos clínicos en pacientes hospitalizados con la enfermedad. Se excluyeron los artículos que no abordaban conjuntamente el tema del estudio, los artículos duplicados en las bases de datos, los artículos de revisión, los artículos basados en ensayos animales in vitro / in vivo, los artículos basados en la medicina tradicional, los estudios de tipo editorial y también los artículos reflexivos. Resultados: De los 210 artículos identificados, se excluyeron 132 por no cumplir los criterios de inclusión, y se seleccionaron para este estudio 78 artículos que pretendían estudiar la eficacia de los medicamentos en ensayos clínicos internacionales. De ellos, 67 en la base de datos PubMed; 6 por SciELO; y, 5 en Lilacs. Se analizaron 49 medicamentos, clasificados en 22 clases farmacológicas. Las principales clases de medicamentos en los estudios fueron: antivirales de acción directa en monoterapia, 8 (16,32%); inmunomoduladores, 7 (14,28%); inmunomoduladores + asociaciones, 2 (4,08%); e, inmunoestimulantes + asociaciones, 2 (4,08%). Conclusión: Los fármacos y sus asociaciones en estudio no presentan una eficacia terapéutica específica para el tratamiento de la COVID-19; sin embargo, los ensayos clínicos indican una mejora de los síntomas clínicos de los pacientes y del tiempo de internamiento. Sin embargo, algunos medicamentos mostraron reacciones adversas significativas, interfiriendo directamente con la seguridad del paciente.A COVID-19 é uma infecção respiratória aguda causada pelo coronavírus SARS-CoV-2, potencialmente grave, de elevada transmissibilidade e de distribuição global. A busca por drogas que apresentam atividade sobre o SARS-CoV-2 é um desafio constante sem precedentes na validação de medicamentos eficazes no tratamento de pacientes acometidos pela COVID-19. Objetivo: Esta revisão integrativa teve como objetivo avaliar trabalhos na literatura científica, envolvendo ensaios clínicos que avaliam a eficácia de drogas já disponíveis no mercado para provável utilização no tratamento da COVID-19. Metodologia: A pesquisa foi realizada no período de abril de 2020 até junho de 2021 nas bases de dados PubMed, SciElo e Lilacs, utilizando os Descritores em Ciências da Saúde (DeCS) “COVID-19”, “SARS-CoV-2”, “Medicamentos”, “Ensaio Clínico”, “Terapêutica”. Os critérios para inclusão dos artigos na pesquisa foram os que apresentaram resumo e texto disponibilizados na íntegra eletronicamente, escritos em inglês, português e espanhol publicados no período de abril de 2020 a junho de 2021, em periódicos científicos e que avaliaram a eficácia de prováveis fármacos no tratamento da COVID-19 e ensaios clínicos em pacientes hospitalizados portadores da doença. Foram excluídos os artigos que não abordaram, em conjunto, o tema do estudo, artigos duplicados nas bases de dados, artigos de revisão, artigos baseados em ensaios in vitro / in vivo em animais, artigos baseados em medicina tradicional, estudos do tipo editorial e também os artigos reflexivos. Resultados: Dos 210 artigos identificados, 132 foram excluídos por não atenderem os critérios de inclusão, sendo selecionados para este estudo 78 artigos que objetivaram o estudo da eficácia de fármacos em ensaios clínicos internacionais. Destes, 67 estavam indexados na base de dados PubMed; 6 pelo SciELO; e, 5 na Lilacs. Foram analisados 49 fármacos, classificados em 22 classes farmacológicas. As principais classes de fármacos em estudos foram: antivirais de ação direta em monoterapia, 8 (16,32%); imunomoduladores, 7 (14,28%); imunomoduladores + associações, 2 (4,08%); e, imunoestimulantes + associações, 2 (4,08%). Conclusão: Os fármacos e suas associações em estudo não apresentaram eficácia terapêutica específica para o tratamento da COVID-19; porém, os ensaios clínicos indicaram melhora dos sintomas clínicos dos pacientes e do tempo de internamento hospitalar. Entretanto, alguns fármacos apresentaram significativas reações adversas, interferindo diretamente na segurança dos pacientes.Research, Society and Development2022-01-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2444510.33448/rsd-v11i1.24445Research, Society and Development; Vol. 11 No. 1; e11611124445Research, Society and Development; Vol. 11 Núm. 1; e11611124445Research, Society and Development; v. 11 n. 1; e116111244452525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/24445/21685Copyright (c) 2022 Tatiana Aparecida Furuzawa; Gabriel Fernando Esteves Cardia; Mariana Vessoni Iwaki; Edivaldo Cremer; Ricardo Alexandre Spironello; Francielli Maria de Souza Silva Comar; Roberto Kenji Nakamura Cumanhttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessFuruzawa, Tatiana Aparecida Cardia, Gabriel Fernando Esteves Iwaki, Mariana Vessoni Cremer, EdivaldoSpironello, Ricardo Alexandre Comar, Francielli Maria de Souza Silva Cuman, Roberto Kenji Nakamura 2022-01-16T18:08:18Zoai:ojs.pkp.sfu.ca:article/24445Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:42:59.854477Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Study of selected drugs in clinical trials in the pharmacological therapy of COVID-19
Estudio de fármacos seleccionados en ensayos clínicos en la terapia farmacológica de la COVID-19
Estudo dos fármacos selecionados em ensaios clínicos na terapia farmacológica da COVID-19
title Study of selected drugs in clinical trials in the pharmacological therapy of COVID-19
spellingShingle Study of selected drugs in clinical trials in the pharmacological therapy of COVID-19
Furuzawa, Tatiana Aparecida
COVID-19
SARS-CoV-2
Medicamentos
Ensayos Clínicos
Terapéutica.
COVID-19
SARS-CoV-2
Medicamentos
Ensaio Clínico
Terapêutica.
COVID-19
SARS-CoV-2
Drugs
Trials Clinicals
Therapeutics.
title_short Study of selected drugs in clinical trials in the pharmacological therapy of COVID-19
title_full Study of selected drugs in clinical trials in the pharmacological therapy of COVID-19
title_fullStr Study of selected drugs in clinical trials in the pharmacological therapy of COVID-19
title_full_unstemmed Study of selected drugs in clinical trials in the pharmacological therapy of COVID-19
title_sort Study of selected drugs in clinical trials in the pharmacological therapy of COVID-19
author Furuzawa, Tatiana Aparecida
author_facet Furuzawa, Tatiana Aparecida
Cardia, Gabriel Fernando Esteves
Iwaki, Mariana Vessoni
Cremer, Edivaldo
Spironello, Ricardo Alexandre
Comar, Francielli Maria de Souza Silva
Cuman, Roberto Kenji Nakamura
author_role author
author2 Cardia, Gabriel Fernando Esteves
Iwaki, Mariana Vessoni
Cremer, Edivaldo
Spironello, Ricardo Alexandre
Comar, Francielli Maria de Souza Silva
Cuman, Roberto Kenji Nakamura
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Furuzawa, Tatiana Aparecida
Cardia, Gabriel Fernando Esteves
Iwaki, Mariana Vessoni
Cremer, Edivaldo
Spironello, Ricardo Alexandre
Comar, Francielli Maria de Souza Silva
Cuman, Roberto Kenji Nakamura
dc.subject.por.fl_str_mv COVID-19
SARS-CoV-2
Medicamentos
Ensayos Clínicos
Terapéutica.
COVID-19
SARS-CoV-2
Medicamentos
Ensaio Clínico
Terapêutica.
COVID-19
SARS-CoV-2
Drugs
Trials Clinicals
Therapeutics.
topic COVID-19
SARS-CoV-2
Medicamentos
Ensayos Clínicos
Terapéutica.
COVID-19
SARS-CoV-2
Medicamentos
Ensaio Clínico
Terapêutica.
COVID-19
SARS-CoV-2
Drugs
Trials Clinicals
Therapeutics.
description COVID-19 is an acute respiratory infection caused by the potentially severe, highly transmissible, globally distributed SARS-CoV-2 coronavirus. The search for drugs that have activity on SARS-CoV-2 is a constant challenge without precedent in the validation of effective drugs in the treatment of patients affected by COVID-19. Objective: This integrative review aimed to assess studies in the scientific literature, involving clinical trials that evaluate the efficacy of drugs already available on the market for probable use in the treatment of COVID-19. Methodology: The search was conducted from April 2020 to June 2021 in the PubMed, SciElo and Lilacs databases, using the Health Science Descriptors (DeCS) "COVID-19", "SARS-CoV-2", "Drugs", "Trials Clinicals", "Treatments". The criteria for inclusion of articles in the search were those with abstract and text available in full electronically, written in English, Portuguese, and Spanish, published from April 2020 to June 2021, in scientific journals, and that evaluated the efficacy of probable drugs in the treatment of COVID-19 and clinical trials in hospitalized patients with the disease. Articles that did not jointly address the topic of the study, duplicate articles in the databases, review articles, articles based on in vitro / in vivo animal trials, articles based on traditional medicine, editorial type studies and also the reflexive articles were excluded. Results: Of the 210 articles identified, 132 were excluded for not meeting the inclusion criteria, and 78 articles that aimed to study drug efficacy in international clinical trials were selected for this study. Of these, 67 were in PubMed, 6 in SciELO, and 5 in Lilacs. A total of 49 drugs were analyzed, classified into 22 pharmacological classes. The main classes of drugs in studies were: direct acting antivirals in monotherapy, 8 (16.32%); immunomodulators, 7 (14.28%); immunomodulators + associations, 2 (4.08%); and immunostimulants + associations, 2 (4.08%). Conclusion: The drugs and their associations under study did not show specific therapeutic efficacy for the treatment of COVID-19; however, clinical trials indicated improvement in patients' clinical symptoms and hospital length of stay. However, some drugs showed significant adverse reactions, directly interfering with patient safety.
publishDate 2022
dc.date.none.fl_str_mv 2022-01-03
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/24445
10.33448/rsd-v11i1.24445
url https://rsdjournal.org/index.php/rsd/article/view/24445
identifier_str_mv 10.33448/rsd-v11i1.24445
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/24445/21685
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 11 No. 1; e11611124445
Research, Society and Development; Vol. 11 Núm. 1; e11611124445
Research, Society and Development; v. 11 n. 1; e11611124445
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052826079199232